Bispecific antibodies having enhanced FVIII cofactor alternative activity

摘要

The present invention provides a light chain amino acid substitution that enhances FVIII cofactor function alternative activity of ACE 910 (Emicizumab), a novel light chain exhibiting FVIII cofactor function alternative activity, and FVIII of a bispecific antibody having a novel light chain. Provided are heavy chain amino acid substitutions that enhance cofactor alternative activity.